These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25633410)

  • 1. Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters.
    Da Silva CG; Honeywell RJ; Dekker H; Peters GJ
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):703-17. PubMed ID: 25633410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
    Brózik A; Hegedüs C; Erdei Z; Hegedus T; Özvegy-Laczka C; Szakács G; Sarkadi B
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):623-42. PubMed ID: 21410427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
    Deng J; Shao J; Markowitz JS; An G
    Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism.
    Joyce H; McCann A; Clynes M; Larkin A
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):795-809. PubMed ID: 25836015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors.
    Neul C; Schaeffeler E; Sparreboom A; Laufer S; Schwab M; Nies AT
    Trends Pharmacol Sci; 2016 Nov; 37(11):904-932. PubMed ID: 27659854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration.
    Krchniakova M; Skoda J; Neradil J; Chlapek P; Veselska R
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors.
    Shao J; Markowitz JS; Bei D; An G
    J Pharm Sci; 2014 Dec; 103(12):3810-3833. PubMed ID: 25308414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.
    Lee CC; Shiao HY; Wang WC; Hsieh HP
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1333-48. PubMed ID: 24921970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.
    Anreddy N; Gupta P; Kathawala RJ; Patel A; Wurpel JN; Chen ZS
    Molecules; 2014 Sep; 19(9):13848-77. PubMed ID: 25191874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
    Tlemsani C; Huillard O; Arrondeau J; Boudou-Rouquette P; Cessot A; Blanchet B; Thomas-Schoemann A; Coriat R; Durand JP; Giroux J; Alexandre J; Goldwasser F
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):785-94. PubMed ID: 25809423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.
    Gay C; Toulet D; Le Corre P
    Hematol Oncol; 2017 Sep; 35(3):259-280. PubMed ID: 27925256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
    Dasanu CA; Padmanabhan P; Clark BA; Do C
    Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.
    Shukla S; Chen ZS; Ambudkar SV
    Drug Resist Updat; 2012; 15(1-2):70-80. PubMed ID: 22325423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
    Terada T; Noda S; Inui K
    Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring.
    Josephs DH; Fisher DS; Spicer J; Flanagan RJ
    Ther Drug Monit; 2013 Oct; 35(5):562-87. PubMed ID: 24052062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice.
    D'Cunha RR; Murry DJ; An G
    J Pharm Sci; 2019 Oct; 108(10):3434-3442. PubMed ID: 31163185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms.
    Isaac M; Siu A; Jongstra J
    Drug Resist Updat; 2011; 14(4-5):203-11. PubMed ID: 21601509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
    Yang K; Fu LW
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of
    Huang KM; Uddin ME; DiGiacomo D; Lustberg MB; Hu S; Sparreboom A
    Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):493-506. PubMed ID: 32276560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.